Karus has developed two innovative classes of cancer therapeutics that act through selective inhibition of the PI3K-p110β/δ and HDAC6 enzymes. These drugs hold great potential for the treatment of a range of solid and hematological tumors.
Our highly experienced management team has a track record of scientific and clinical excellence in small molecule drug design and development. We have, to date, created two therapeutic programs and produced two clinical agents which have considerable potential to be best-in-class agents for the treatment of cancer. Our programs are underpinned by a broad, internally-generated and wholly-owned intellectual property portfolio.
Karus is supported by a syndicate of world class, life science investors from the US and Europe: